Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
Key facts
- Who runs it
- Victoria Biomedical Research Institute
- Where
- Kenya1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 1,116 people, planned
- Started
- 20 Jan 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Artemether lumefantrine tablets
- Artemether Lumefantrine and Imatinib Mesylate
- Record updated
- 29 June 2026
Who can take part
- Age
- 1 year to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (26)Hide the full registry criteria
Who can take part
- For Part 1 and 2 of the study design, all individuals must meet all the inclusion criteria below:
- Patients diagnosed with symptomatic mild to moderate P. falciparum malaria with a parasite density of >= 5000 parasites/μl
- Adult male, age 18-55 years old or adult female, age 18-55 years that are post-menopausal, or test negative on a pregnancy test and will be on active birth control through to the end of the follow up period
- Provision of informed consent and agrees to hospital admission for 48-72hrs
- Good health condition other than malaria
- The patient has not taken anti-malarial drugs in the past 4 weeks; For Part 3 of the trial, all individuals must meet all the inclusion criteria below:
- Patients diagnosed with symptomatic mild to moderate P. falciparum malaria and a parasite density of >= 5000 parasites/μl
- Age 12 months to below 18 years
- Presented by parent or legally accepted representative (LAR) who has consented to the participation of the child in the trial and agrees to hospital admission for 48-72hrs
- Hb levels > 5mg/dL
- Child has not taken anti-malarial drugs in the past 6 weeks
Who cannot take part
- Concomitant infection by plasmodium species other than P. falciparum
- Concomitant use of medicines, including:; medicines used to treat high cholesterol (such as atorvastatin, lovastatin, simvastatin); medicines used to treat hypertension and heart problems (such as diltiazem, nifedipine, nitrendipine, verapamil, felodipine, amlodipine); medicine used to treat HIV (antiretroviral medicines) including protease inhibitors (such as amprenavir, atazanavir, indinavir, nelfinavir, ritonavir), non-nucleoside reverse transcriptase inhibitors (such as efavirenz, nevirapine); medicines used to treat microbial infections (such as telithromycin, rifampicin, dapsone); medicines used to help you fall asleep: benzodiazepines (such as midazolam, triazolam, diazepam, alprazolam), zaleplon, zolpidem; medicines used to prevent/treat epileptic seizures including barbiturates (such as phenobarbital), carbamazepine or phenytoin; medicines used after organ transplantation and in autoimmune diseases (such as cyclosporin, tacrolimus); nefazodone (used to treat depression); aprepitant (used to treat nausea)
- Symptoms and signs of severe or complicated malaria including:; significant confusion or impaired consciousness (including unarousable coma); multiple convulsions (more than two episodes within 24 hours),; respiratory distress; circulatory collapse (systolic blood pressure <80mm Hg with evidence of impaired perfusion); clinical jaundice plus evidence of other vital organ dysfunction; simultaneous infection of unrelated origin
- Other neurological or psychiatric symptoms or disorders
- Abnormal bleeding
- Resting heart rate lower than 55 or higher than 100 bpm
- History of cardiac disease
- Symptoms and signs of infection such as pneumonia, dengue fever, and other viral or bacterial infection
- Patients with symptoms of gastrointestinal infections or any sign of malabsorption that may interfere with drug absorption
- Signs, symptoms and laboratory results of impairment of vital organs such as liver, lungs, kidney and cardiovascular system
- Abnormal blood chemistry:; hemoglobin < 9.0 g/dL in adults or < 5.0 g/dL in children 12 months-18 years; WBC not in the range of 4800-10,000/mm3; RBC if < 4.0x106/ mm3; Platelet < 1.3x105/ mm3; ALAT not in the normal range (4 to 36 U / l); ASAT not in the normal range (8 to 33 U / l); Total bilirubin 0.1 to 1.2 mg / 100 ml; Serum protein if < 5.5 g/dL
- Prospective study participant, LAR and/or impartial witness (where applicable) declines to provide informed consent
- Parasite density > 200,000 parasites /μl
- In the case of female participants: currently pregnant or lactating
- Inability to attend/meet study staff on follow up visits
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Malaria
This trial is currently available in Kenya.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa
The 5 groups in the trial
- Artemether Lumefantrine AloneExisting treatment, for comparison
Standard 3-day course. Used as control in all parts.
Treatment: Artemether lumefantrine tablets
- Artemether Lumefantrine and Imatinib 400mg Twice Daily (3 days)Treatment being tested
3-day course with imatinib 400mg twice daily.
Treatment: Artemether Lumefantrine and Imatinib Mesylate
- Artemether Lumefantrine and Imatinib (Optimal Dose, 3 days)Treatment being tested
3-day course with optimal dose determined from Part 1.
Treatment: Artemether Lumefantrine and Imatinib Mesylate
- Artemether Lumefantrine and Imatinib (Optimal Dose, 2 days)Treatment being tested
2-day imatinib course (optimal dose) with 3-day AL.
Treatment: Artemether Lumefantrine and Imatinib Mesylate
- Pediatric: Artemether Lumefantrine and Imatinib (Weight-based)Treatment being tested
Weight-based imatinib (340 or 260 mg/m²/day, max 600mg) plus weight-based AL for 3 days.
Treatment: Artemether Lumefantrine and Imatinib Mesylate
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluating the Safety and Efficacy of Imatinib in Combination With Artemether and Lumefantrine for Treatment of Uncomplicated Malaria
- Criteria questions
- Built from NCT07559370, who can take part
- Record updated
- 29 June 2026